Drugs and patents in ATC class D05BA - Psoralens for systemic use

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
8-MOP	methoxsalen
METHOXSALEN	methoxsalen
OXSORALEN-ULTRA	methoxsalen
UVADEX	methoxsalen
OXSORALEN	methoxsalen
>Tradename	>Generic Name

Last updated: June 24, 2026

Executive summary: ATC D05BA covers systemic psoralens used in photochemotherapy (notably PUVA and related regimens). The commercial market is dominated by older, largely off-patent or expiring-origin products, while the competitive and IP focus has shifted toward (1) reformulated or controlled-release psoralens, (2) method-of-use claims tied to specific phototherapy protocols, and (3) regulatory exclusivity tied to specific FDA product approvals rather than active-substance exclusivity. Patent estates are generally thin in the near term for global entry, with the main entry barriers typically arising from formulation, process, and use-specific claim scope rather than broad composition-of-matter coverage.

Which patents protect psoralens for systemic use (ATC D05BA) in PUVA and systemic photochemotherapy?

ATC D05BA “psoralens” for systemic use is most commonly associated with psoralen active ingredients used with UV-A light in PUVA-like approaches. In practice, patent protection in this class tends to cluster around four themes:

1) Composition-of-matter vs. reformulation

Original psoralen actives (e.g., psoralen and its naturally occurring derivatives used systemically) have a high likelihood of being outside active patent coverage, given the age of the therapeutic class and typical filing timelines.
Modern patent activity (when present) more often centers on specific solid forms, salt/derivative selection, purity specifications, particle-size or polymorph control, and dose-unit manufacturing controls.

2) Method-of-use patents

Patent filings frequently target treatment regimens:
- Timing between psoralen administration and UV exposure.
- UV-A dosing schedules and cumulative dose logic.
- Patient selection criteria or adaptive dosing frameworks.
These can be enforceable even when the active ingredient is old, because claims are directed to how the drug is used.

3) Formulation and delivery patents

For systemic photochemotherapy, formulation improvements focus on:
- Bioavailability and onset time alignment with UV-A exposure.
- Gastrointestinal tolerability (reduced nausea, improved compliance).
- Controlled-release approaches to synchronize plasma exposure with treatment slots.

4) Manufacturing process patents

Process claims remain a common source of residual IP:
- Crystallization or purification steps.
- Batch-to-batch consistency controls.
- Scale-up and validation methods tied to active quality.

Practical takeaway

In ATC D05BA, the patent “center of gravity” usually shifts away from broad composition-of-matter claims toward formulation + regimen claims that can still block certain product or protocol combinations.

How strong is the patent estate for ATC D05BA psoralens for systemic use?

High-level scoring pattern: residual patent strength is typically moderate-to-low at the active-substance level but case-specific at the product and method layers.

What determines whether the estate is strong or weak

Claim breadth
- Broad claims covering “psoralen for systemic use in PUVA” are less common than narrow claims targeting specific schedules, forms, or manufacturing steps.
Remaining claim term
- Even with method-of-use coverage, enforceability depends on whether claims filed late in the lifecycle still have term remaining.
Regulatory linkage
- In markets where FDA or EMA approvals exist for specific dosage forms, remaining exclusivity for that specific product can extend market control even if the active ingredient is off-patent.
Design-around feasibility
- If the claims target precise UV-A dosing timing or plasma exposure curves, competitors can sometimes enter with alternative schedules (subject to medical practice and litigation risk).

Featured snippet answer

Patent strength in ATC D05BA is usually strongest in formulation/process and specific regimen protocol claims, and weakest in composition-of-matter for the old active ingredient.

When does psoralen systemic therapy lose exclusivity, and what timelines drive market entry?

Core market timing drivers for D05BA systemic psoralens:

Patent expiration (composition-of-matter, formulation, method-of-use)
Regulatory exclusivity (if any still tied to specific FDA or comparable approvals)
Patent term adjustments and pediatric extensions that can extend enforceability for certain filings

Typical timeline pattern in this drug class

Active ingredient patents: expired or expiring long before modern market dynamics.
Formulation and method claims: can stagger expiries, creating windows where a specific product presentation or protocol remains protected.
Generic entry: often possible once the specific protected formulation or regimen claim set is cleared, but timing can depend on whether challengers can avoid claim scope.

How to read “loss of exclusivity” for systemic psoralens

Market control typically does not end at a single date. Instead it ends when:

The last enforceable patent covering the commercialized dosage form or a materially similar one expires, and
Any regulatory exclusivities tied to that specific approved product lapse, and
Any pending Paragraph IV or equivalent challenges resolve without entry-blocking injunctions.

What generic entry risks exist for ATC D05BA psoralens for systemic use?

Generic entry risk depends on whether the key patents are:

Composition-of-matter (high barrier, long survival)
Formulation/process (medium barrier, but design-around often possible)
Method-of-use/regimen (high litigation risk for certain protocol claims, but entry can still occur with different labeling or practice patterns)

Common entry pathways

ANDA-like generic submissions for small-molecule psoralens where applicable
Switching from the protected presentation (e.g., different dosage form strength, excipients, or release profile)
Labeling carve-outs: entry with narrower indication language to avoid method-of-use infringement

Litigation and injunction risk

If a competitor challenges patents tied to the approved regimen or timing instructions, the risk of injunction increases.
If the competitor instead introduces a distinct formulation presentation, litigation may shift to product design and process equivalency rather than broad “same drug” claims.

What is the Orange Book status of systemic psoralens in the US?

Orange Book status requires product-by-product listing. For D05BA as a class, the key business reality is that Orange Book protection (patents and exclusivity) tends to be product-specific even when the active ingredient is old.

Market-relevant interpretation

If an Orange Book listing exists for a psoralen product, it is likely tied to:
- Formulation/patent claims
- Use claims tied to labeled regimen
- Process claims supporting manufacturing
For many psoralen products, Orange Book protection may already be expired, leaving no current statutory exclusivity but leaving residual patent litigation risk if method claims remain.

Which companies are challenging psoralen patents or planning biosimilar-type strategies?

ATC D05BA includes small-molecule psoralens, not biologics. “Biosimilar” strategies are typically not applicable. The practical competitive challengers are generic manufacturers and alternative-formulation sponsors.

Competitive pattern

Generic manufacturers target:
- Off-patent dosage strengths
- Different excipient compositions
- Different release profiles to avoid formulation infringement
Brand holders (or rights holders) defend through:
- Narrow claim interpretation
- Injunction seeking tied to core formulation or method-of-use claims
- Settlement licensing where competitors want to launch in a defined window

What patent litigation affects psoralens for systemic use (D05BA) and what outcomes matter?

In this class, litigation outcomes usually matter in three practical ways:

Entry date control through injunctions or settlement entry carve-outs
Scope of “design-around” permitted for alternative formulation and labeling
Claim construction defining what constitutes infringing regimen timing or formulation equivalence

Business signal

Where litigation has produced:

Settlements with agreed launch dates, entry may align to those dates rather than to the statutory expiration calendar.
Narrow favorable constructions for the patentee, design-arounds become harder and launch timing shifts.

How do formulation patents for systemic psoralens compare across major dosage forms (tablets, capsules, solutions)?

Formulation patents can differ substantially by dosage form, and that drives competitive strategies.

Tablet/capsule oriented protection

Solid form stability
Dissolution rate and bioavailability control
Excipient systems linked to absorption kinetics aligned to UV-A scheduling

Solution oriented protection

Stability in solution
Container closure integrity
Purity and degradation profile control

Key commercial implication

If the dominant commercial product is a specific dosage form, generic entrants often face a higher hurdle unless they can match dissolution/absorption characteristics without triggering formulation or process claims.

Method-of-use patents for PUVA and related systemic psoralen regimens: what do they claim?

Method-of-use claims in psoralens generally focus on protocol logic rather than the molecule itself.

Typical claim elements

Administration timing relative to UV-A exposure
UV-A dose per session and cumulative dose targets
Patient stratification rules and adjustment triggers
Use in specific dermatoses (depending on the labeled or clinically used indications)

Design-around angles

Labeling changes: remove or narrow instruction elements tied directly to the claimed regimen
Alternative timing or dosing: if claims are precise, small deviations may reduce infringement
Different UV sources: some claims can be tied to certain UV-A device parameters

How does ATC D05BA compare with other phototherapy-linked dermatology classes on patent durability?

In dermatology phototherapy:

Systemic biologics (where present in other classes) create longer-lasting IP because biologics often have deeper patent coverage and exclusivity layers.
Systemic psoralens typically have older actives, so durability is more dependent on specific formulation and method-of-use rather than broad composition-of-matter.

Bottom line

ATC D05BA is usually a residual-IP, protocol-sensitive market rather than a “long exclusivity” market.

Revenue exposure and competitive landscape: what matters for payers, hospital systems, and procurement?

Buying dynamics for systemic psoralens are procurement- and protocol-driven:

Hospitals buy based on:
- Treatment schedules
- Availability of dosing time windows for UV-A sessions
- Pharmacy handling requirements (stability, storage, compatibility)
Payers focus on:
- Total cost per treatment course
- Whether generics can reduce unit costs without causing protocol deviations that increase resource usage

Market risks

Supply continuity risk can raise costs even when IP expires.
Formulation-specific supply constraints can cause substitution delays for hospitals.

Which countries provide the main IP barriers for systemic psoralens (D05BA)?

Patent enforcement and commercial barriers track where:

patents were filed with active claims,
regulatory approvals for specific dosage forms exist,
and enforcement is practically feasible.

Typical enforcement geography

US for ANDA-type litigation dynamics and Paragraph IV frameworks
EU for national patent enforcement and central regulatory referencing
UK and select high-income markets where dermatology procurement is concentrated

What formulation and manufacturing IP barriers can delay generic launches?

Even with expired active-substance patents, launch can be delayed by:

Formulation patents controlling release and dissolution
Process patents covering purification and crystallization
Device- or regimen-linked labeling that triggers method-of-use infringement theories
Regulatory data and bridging demands for different dosage forms

Business impact

Competitors may delay launch until they can certify non-infringement or obtain a settlement.
If the protected formulation is the only clinically preferred one, design-arounds can be commercially unattractive even if legally permissible.

Key Takeaways

ATC D05BA systemic psoralens typically have limited remaining active-substance patent durability; protection is more often concentrated in formulation/process and method-of-use regimen claims.
Market entry timing is driven less by a single “patent expiry date” and more by the last enforceable product presentation and protocol-specific claims, plus any regulatory exclusivity tied to specific approved products.
Generic risk is usually medium at the active level but can be high when competitors replicate a protected dosage form or labeled regimen instructions without design-around.
For strategic planning, treat D05BA as a residual-IP and protocol-sensitive landscape where settlements and claim construction can define the real launch calendar.

FAQs

Do systemic psoralens have patent protection tied to specific UV-A timing windows?

Yes. Method-of-use claims commonly target administration timing relative to UV-A exposure and may include session and cumulative dose parameters.

Can a generic systemic psoralen enter with different excipients without infringing formulation patents?

It depends on claim scope. Formulation patents often cover dissolution/bioavailability-linked excipient systems and manufacturing controls, so “different excipients” can still infringe if functional equivalence is claimed.

What is the biggest reason psoralen generic launches stall after active ingredient patents expire?

Residual patents on the approved dosage form and regimen-related instructions are the most frequent stall points, supported by potential injunction risk in product-specific litigation.

Are biosimilars relevant for ATC D05BA psoralens?

No. D05BA systemic psoralens are small molecules, so the competitive and legal framework is generic-equivalent, not biosimilar.

How do hospital procurement cycles affect the commercial impact of patent expiry?

Hospital formularies and protocol workflows can delay adoption of cheaper alternatives even after legal barriers lift, especially if substitution requires operational changes to dosing and UV session coordination.

References (APA)

European Medicines Agency. (n.d.). European public assessment reports and product information. EMA.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA database. FDA.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD index. WHO.